TY  - JOUR
AU  - Biederstädt, Alexander
AU  - Bassermann, Florian
AU  - Hecker, Judith S
TI  - Allogeneic CAR-engineered cellular therapy for relapsed and refractory large B cell lymphoma: a systematic review and meta-analysis.
JO  - Frontiers in immunology
VL  - 16
SN  - 1664-3224
CY  - Lausanne
PB  - Frontiers Media
M1  - DKFZ-2025-01510
SP  - 1585556
PY  - 2025
AB  - Relapsed/refractory (r/r) large B-cell lymphoma (LBCL) remains a difficult-to-treat disease with limited treatment options and high unmet clinical need, necessitating the development of new therapies with greater potency and broader applicability. While autologous chimeric antigen receptor (CAR)-T cell therapies have transformed the treatment landscape, 60-65
KW  - Humans
KW  - Immunotherapy, Adoptive: methods
KW  - Immunotherapy, Adoptive: adverse effects
KW  - Receptors, Chimeric Antigen: immunology
KW  - Receptors, Chimeric Antigen: genetics
KW  - Lymphoma, Large B-Cell, Diffuse: therapy
KW  - Lymphoma, Large B-Cell, Diffuse: immunology
KW  - Treatment Outcome
KW  - Neoplasm Recurrence, Local: therapy
KW  - Killer Cells, Natural: immunology
KW  - Killer Cells, Natural: transplantation
KW  - Transplantation, Homologous
KW  - CRISPR gene editing (Other)
KW  - adoptive cell therapy (ACT) (Other)
KW  - allogeneic CAR-NK cells (Other)
KW  - allogeneic CAR-T cells (Other)
KW  - cellular engineering (Other)
KW  - clinical trial (Other)
KW  - large B cell lymphoma (Other)
KW  - precision gene editing (Other)
KW  - Receptors, Chimeric Antigen (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:40698082
C2  - pmc:PMC12279871
DO  - DOI:10.3389/fimmu.2025.1585556
UR  - https://inrepo02.dkfz.de/record/303085
ER  -